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Abstract
The aim of this pilot clinical trial was to evaluate the safety of a new formulation of prolonged-release Pirfenidone (PR-PFD) in chronic kidney 
disease (CKD), specifically focal and segmental glomerular hyalinization (FSGH). Open-label, pilot, nonrandomized trial. Eighteen patients 
previously diagnosed with CKD stages 1– 5 according to “Kidney Disease: Improving Global Outcomes” were enrolled in the study. Target dos-
age of PFD was 1200 mg twice a day in the form of prolonged-release tablets to reach a full dosage of 2400 mg daily. Clinical trial was carried 
out for 60 months to evaluate the safety and efficacy of a newly formulated PR-PFD in patients with CKD. After the treatment for 60 months, 
it was found that PR-PFD kept renal function from declining significantly in CKD patients, as the glomerular filtration rate (GFR) showed only 
minimal variations throughout the study. Estimated glomerular filtration rate (eGFR) showed no differences at both baseline and the end points. 
Proteinuria improved, and creatinine, cystatin C, urea, hemoglobin and hepatic transaminases remained constant without any considerable 
changes across the study. Minor side effects were noticed when compared with those found in previous studies, indicating an increased tolerance 
to this pharmaceutical formulation of PFD. Prolonged-released PFD could be safely used as an adjuvant therapy in patients with CKD.
Registry number was obtained from ClinicalTrials.gov (NCT02408744).
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Introduction
Chronic kidney disease (CKD) is a general term to classify 
a group of disorders affecting the structure and function 
of the kidney, present for >3 months, with implications for 
health. Recently, the “Kidney Disease: Improving Global 
Outcomes” (KDIGO) group defined CKD on the basis of 
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Sharma et al. confirmed a strong association between an 
increase of several protein biomarkers considered to be part 
of the inflammatory response (TNF, sTNF-R1, IFN-γ, and 
IL-1) and GFR decline, suggesting a relevant inverse rela-
tionship (14).
Lancaster et al. performed an integrated analysis of 
safety data from five clinical trials evaluating pirfenidone in 
patients with IPF. A total of 1299 patients were included in 
the analysis. The median duration of exposure was 1.7 years, 
and the mean daily dose was 2053.8 mg. They concluded that 
long-term treatment with regular PFD in patients with IPF 
is safe and generally well tolerated (27). However, there is a 
need for clinical studies demonstrating the safety of this new 
formulation of prolonged-release PFD administration in 
patients with CKD.
Thus, the aim of this pilot clinical trial was to evaluate the 
safety and preliminary evidence of efficacy of a new formu-
lation of prolonged-released PFD in CKD, specifically focal 
and segmental glomerular hyalinization (FSGH). Our find-
ings suggest that prolonged-release PFD could be used as an 
adjuvant therapy in patients with CKD.
Materials and Methods
Study design
This open-label, pilot, nonrandomized trial was originally 
designed for 12 months. As the study progressed, we decided 
to extend it up to 60-months’ duration to evaluate long-term 
safety and preliminary outcomes in the efficacy of PFD 
[5-methyl-1-phenyl-2-(1H)-pyridone] taken orally daily as a 
potential adjuvant therapy in CKD. The target dosage of PFD 
was 1200 mg twice a day (b.i.d.) in the form of prolonged- 
release tablets (PR-PFD) according to the body surface area 
(m2 BS) of each patient to reach a full dosage of 2400 mg 
daily. Therapy was initiated at 600 mg b.i.d. and escalated to 
the full dosage after 3 weeks when symptoms were controlled. 
PR-PFD was manufactured according to standard Good 
Manufacturing Practices (GMPs), Good Laboratory Prac-
tices (GLPs), and previously accepted sanitary regulations 
enforced by the Federal Commission for Protection against 
Sanitary Risks (COFEPRIS) (Mexican Minister of Health).
Regulatory authorities and ethics committees from the 
Centro de Estudios de Investigación Básica y Clínica S.C. 
and Hospital Real San José approved the conduction of this 
study (along with patient sheets and consent forms) with the 
registry number 2009-010. Furthermore, a registry number 
was obtained from ClinicalTrials.gov (NCT02408744).
The study group included patients previously diagnosed 
using renal biopsy with FSGH from Hospital Real San José 
and Dr. Ojeda-Duran’s office. All participants received a major 
explication of the methodology to be used across the study and 
signed consent forms prior to the initiation of the protocol.
either evidence of kidney damage (proteinuria, hematuria, 
or anatomical abnormality) or the presence of kidney injury 
or substantially decreased glomerular filtration rate (GFR 
<60 mL/min per 1.73 m2, stage 3a) for ≥3 months, regardless 
of cause. CKD has been classified into five stages based on 
the level of GFR (1–3) and based on the albuminuria cate-
gory (A1–A3) (>30 mg/g or >3 mg/mmol, stage A2) (3).
In terms of epidemiology, CKD is a global public health 
issue, with an incidence of more than 200 cases per million 
per year in many countries, with a rising prevalence, poor 
outcomes, and high costs (4–6). CKD has a high global 
prevalence between 11 and 13%, with the majority being 
stage 3 (7). Unfortunately, mortality rates remain above 20% 
per year with the use of dialysis, reflecting the increased asso-
ciation between reduced GFR and increased risk of death, 
cardiovascular events, and hospitalization (8).
The causes leading to CKD are usually associated with old 
age, diabetes, hypertension, obesity, and cardiovascular dis-
ease (5, 7). In spite of the heterogeneity of the underlying 
disease, renal fibrosis (characterized by glomerulosclerosis 
and tubulointerstitial fibrosis) characterizes the final com-
mon manifestation of virtually all progressive renal diseases, 
chronic allograft nephropathy, and renal aging (9–11). Up 
till now, the standard of care for diabetic and nondiabetic 
nephropathies has been the use of inhibitors of the renin- 
angiotensin system (RAS) (12, 13). However, these inhib-
itors when used in maximum doses have severe side effects 
(hyperkalemia and decreased renal blood flow). Eventually, 
they might decrease the rate of disease progression, but they 
cannot improve renal fibrosis (14). Therefore, in recent years, 
the study of the roles of TGF-β1 and TNF-α, implicated in 
the activation of cellular pathways responsible for the devel-
opment of renal diseases (15), has been instrumental in the 
development of new strategies to control fibrogenic activity 
of TGF-β1 as a promising approach (11).
Pirfenidone (PFD) is a pyridone derivative with wide 
anti-fibrotic and anti-inflammatory effects by modulation of 
diverse cytokines, such as TGF-β1, IL-1, IL-4, IL-6, IL-8, 
IL-13, IFN-γ, and TNF-α. Also, PFD reduces the expression 
of intracellular adhesion molecule-1 (ICAM-1) and enhances 
the expression of anti-inflammatory cytokines like IL-10 
(16–18). Previous studies using PFD in animal models of 
renal damage have demonstrated encouraging results in tub-
ulointerstitial fibrosis due to unilateral ureteral obstruction 
(UUO), diabetes (19), damage induced by cyclosporin, and 
in streptozotocin-induced diabetic rats (20–22). Besides, PFD 
is able to limit the fibrogenic potential of tacrolimus- induced 
nephrotoxicity (23), controls chronic anti-glomerular base-
ment membrane glomerulonephritis (anti-GMB GN) (24). In 
clinical trials, standard-release pirfenidone has been used to 
treat CKD, and it has been tested in focal segmental glomer-
ulosclerosis (25) and diabetic nephropathy with promising 
results (14, 26).
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Eighteen out of 30 selected patients with evidence of kid-
ney damage (proteinuria, hematuria) unabated for more than 
3 months and diagnosed with CKD (FSGH) were included 
in the study according to the inclusion criteria. All patients 
continued their concomitant management based on a low 
protein, phosphate, and purine diet; restriction on the intake 
of sodium, potassium, and liquids per individual case; 
keto-analogues of essential amino acids; phosphate chelat-
ing agents (calcium acetate); and treatment with angiotensin- 
converting enzyme (ACE) inhibitors of angiotensin- receptor 
blockers (ARBs).
The primary outcome was to evaluate the use of PR-PDF 
in the rate of renal damage progression in patients with pri-
mary nephropathy (Stages 1–5 of the KDIGO classification) 
by determining GFR. The secondary outcomes were to mea-
sure renal function monitored by cystatin C, PR-PFD effect 
on proteinuria, and determination of adverse drug events in 
patients, determining the safety of the PR-PFD administra-
tion in this type of patients.
Statistical analysis
Data are presented as the mean±standard deviation (SD). 
Statistical significance was determined with one-way 
ANOVA and Bonferroni post-hoc test. Intention to treat 
analysis (ITT) was also performed. Statistical analysis was 
performed using Prism software (GraphPad Prism, CA, 
USA). Significance was defined as a P value < 0.05.
Results
Eighteen patients, comprising 10 women and eight men 
(mean age = 24.4 years old, SD ± 9.7), previously diagnosed 
with CKD (FSGH) were enrolled in the study (Figure 1). All 
Method of recruitment, recruitment  
setting, settings and location where the  
data were collected
Given that this protocol was planned as a pilot, non-
randomized study, we opted for a population of  30 sub-
jects aged between 10 and 40 years, of  both genders, 
who were scrutinized from July 2009 up to March 2010. 
The 18 patients who were finally included were recruited 
at Dr.  Ojeda- Duran’s office and Hospital San Jose at 
 Guadalajara,  Mexico, and followed up for 5 years. In addi-
tion, Case Report Forms (CRFs) were filled up accordingly 
and kept along with the medical files. All data were stored 
in an electronic data base.
Medication was supplied in the form of 600 mg tablets of 
PR-PFD packed in bottles of 120 tablets each. Adherence 
to the treatment was encouraged by the principal investiga-
tor with the help of a psychology counselor, and the records 
of medicine intake were scrutinized on a monthly basis. An 
accurate record of the shipment and delivery of the study 
medication was kept in a medication accounting book. Also, 
a precise record of the dates and amounts of the study med-
ication given to each subject was available at all times for 
inspection.
Study group
Patients enrolled for treatment initially received 600 mg 
PR-PFD b.i.d. before the dosage being escalated after 3 
weeks, once the symptoms permitted tolerance to full dos-
age (2400 mg/day), although all patients were instructed to 
take PR-PFD after meals to diminish gastrointestinal side 
effects for 60 months. Clinical evaluation was performed 
on a monthly basis, and laboratory tests were programmed 
at the time of enrollment and in months 2, 4, 6, 9, and 12, 
and then every 12 weeks until month 60. The baseline testing 
consisted of complete blood count, chemistry profile, includ-
ing  Cystatin c, hepatic panel, amylase, creatinine, and a 24 h 
urine collection to determine proteinuria.
Inclusion criteria used in this study were the following: (i) 
patients aged between 10 and 40 years with CKD; (ii) diag-
nosis of CKD stage 1–5 according to KDIGO definition and 
classification; (iii) no glucocorticoids, cyclophosphamide, 
mycophenolate, or other immunosuppressive drugs for at 
least 2 months before starting PR-PFD administration; and 
(iv) signing of consent forms.
Exclusion criteria were the following: (i) known intoler-
ance to PR-PFD; (ii) CKD stage 5 according to KDIGO 
classification; (iii) posttransplant patients; (iv) history of 
peptic ulcer within 6 months of transplant; (v) history of 
cerebrovascular disease within 6 months of transplant; (vi) 
evidence of hepatic disease; (vii) pregnancy or breast feed-
ing; and (viii) malignancy.
Clinical
evaluation/laboratory
test
Clinical
evaluation/laboratory
test (month
2,4,6,9,12,15,18,21,
24...60)
CKD Patients enrolled
(N = 18) (Signed
consent forms)
600 mg PR-PFD
b.i.d (for 3 weeks)
1200 mg PR-PFD
b.i.d (for 60
months)
Statistical analysis
Figure 1. Study flowchart. Eighteen CKD patients were 
enrolled, 14 patients completed the 60-month treatment with 
prolonged-release Pirfenidone.
CKD: chronic kidney disease; PR-PFD: prolonged-release 
Pirfenidone.
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Table 1. Patient characteristics at baseline.
Patient Age 
(years)
Sex Diagnostic Diagnostic test Biopsy 
results
CKD 
stage 
Creatinine 
depuration 
mL/min
eGFR (mL/
min/1.73 m2)
1 15 F SNS/PG RB and RDU FSGH 3b 38.17 40
2 31 F SNS/PG RB and RDU FSGH 3a 46.69 46
3 18 F SNS/PG RB and RDU FSGH 3b 40.81 31
4 20 M SNS/PG RB and RDU FSGH 3b 62.43 43
5 14 M SNS/PG RB and RDU FSGH 3a 54.5 55
6 18 F SNS/PG RB and RDU FSGH 4 17.71 18
7 11 F SNS/PG RB and RDU FSGH 1 96.45 153
8 17 M SNS/PG RB and RDU FSGH 4 35.63 29
9 10 F SNS/PG RB and RDU FSGH 1 114.22 156
10 24 M SNS/PG RB and RDU FSGH 3b 55.76 37
11 38 M SNS/PG RB and RDU FSGH 3b 47.93 32
12 10 M SNS/PG RB and RDU FSGH 3a 23.89 59
13 12 F SNS/PG RB and RDU FSGH 3a 28.76 52
14 43 M SNS/PG RB and RDU FSGH 3b 41.23 32
15 34 F SNS/PG RB and RDU FSGH 2 86.5 60
16 36 F SNS/PG RB and RDU FSGH 4 29.82 28
17 21 M SNS/PG RB and RDU FSGH 3a 48.35 45
18 19 F SNS/PG RB and RDU FSGH 3b 53.24 31
SNS/PG: secondary nephrotic syndrome, primary glomerulopathy; RB: renal biopsy; RDU: Renal Doppler Ultrasound; 
FSGH: focal and segmental glomerular hyalinization; CKD: chronic kidney disease; eGFR: estimated glomerular filtration 
rate; Creatinine depuration was calculated by COCKROFT-GAULT formula. 
patients tolerated fairly well a dose of 2400 mg/day of PR-PFD 
across the study. During this time, two patients decided 
to stop therapy after 27 months of treatment, one patient 
stopped therapy after 45 months since he became a transplant 
recipient, and one patient was excluded from the study after 
54 months of treatment due to loss of adherence. Table 1 is a 
summary of the clinical characteristics of patients at baseline 
protocol. The intention to treat (ITT) analysis includes all the 
18 patients with CKD (FSGH), and per- protocol (PP) anal-
ysis includes 77.7% of patients who completed the treatment 
originally (14 patients ended treatment after 60 months). The 
study group accounted for a mean time of CKD evolution of 
52.4 months (SD ± 10.8) before enrollment in the study. The 
ITT was performed for biochemistry and clinical parameters 
(Table 2). None of the patients dropped out from the study 
due to severe side effects of PR-PFD.
The ITT for the 18 patients regarding laboratory measure-
ments showed the next data.
GFR from baseline period to the end of study was eval-
uated. At the time of admission, the mean GFR was 52.8 
mL/min/1.73 m2, after 12 months was 61.2 mL/min/1.73 
m2, after 36 months’ follow-up was 56.3 mL/min/1.73 
m2, and at the end of the study (60 months) was 57.0 mL/
min/1.73 m2, as reported in the laboratory tests. The mean 
difference between baseline to month 12 of treatment was 
+8.4 mL/min/1.73  m2, between month 12 to month 36 
was  −4.8 mL/min/1.73 m2, while from month 36 to month 
60 was +0.7 mL/min/1.73 m2, and the mean change between 
baseline to end of the study (month 60) was +4.2 mL/
min/1.73 m2. It is important to note that none of the patients 
included in the study showed a significant decline in GFR 
during the 60 months of study in spite of intrinsic kidney 
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damage (Table 2). In  addition, estimated glomerular filtra-
tion rate (eGFR) was calculated by the abbreviated Modi-
fication of Diet in Renal Disease (MDRD) equation: 186 × 
(Creatinine/88.4)−1.154 × (Age)−0.203 × (0.742 if  female) × (1.210 
if  black), and no significant differences were found: median 
baseline values were 52 mL/min/1.73 m2 as compared after 60 
months (median 50 mL/min/1.73 m2) (Table 1 and Table 3).
ITT in creatinine values reported at the time of enrollment 
revealed a mean of 2.0 mg/dL, while at the end of the study 
creatinine was 2.6 mg/dL, which suggest that PFD treatment 
ensured steady levels of serum creatinine throughout the 
entire clinical trial (Table 2).
The ITT analysis of serum cystatin C, a small mole-
cule used as a new endogenous filtration marker, revealed 
minimal variations along the study; patients’ baseline was 
1.7  mg/L and at the end of the study, the mean value was 
1.8 mg/L (Table 2).
Other laboratory tests carried out were the 24 h protein 
urine test to assess proteinuria levels, which presented a 
slight but relevant reversal from baseline to the end of study. 
The ITT analysis showed the same value of 3.3 g/24 h at 
baseline and at the end of the study (Table 2), while PP anal-
ysis showed 4.03 g/24 h and 3.3 g/24 h from baseline to the 
end of the study, respectively (Table 4); this situation showed 
additional evidence that proteinuria levels can be maintained 
without changes using PR-PFD (Figure 2).
Urea levels remained with minor changes throughout 
the study. There were no significant variations in hemoglo-
bin and/or hepatic transaminases, and all measurements 
remained within normal parameters (Tables 2 and 4).
Adverse events
Only minor events were reported throughout the study, con-
sisting of nausea 38.8% (7/18), vomit, 16.6% (3/18), dyspep-
sia or abdominal discomfort 11.1% (2/18), fatigue 11.1% 
Table 2. ITT analysis of mean laboratory measurements throughout the study.
Basal  
(SD)
Month 12  
(SD)
Month 24  
(SD)
Month 36  
(SD)
Month 48  
(SD)
Month 60 
(SD)
GFR (mL/min/1.73 m2) 52.8 (24.6) 61.2 (37.0) 57.4 (33.3) 56.3 (42.2) 53.0 (42.9) 57.0 (47.7)
Creatinine (mg/dL) 2.0 (0.8) 1.9 (0.9) 1.9 (0.8) 2.2 (1.0) 2.5 (1.3) 2.6 (1.5)
Cystatin C (mg/L) 1.7 (0.6) 1.6 (0.7) 1.7 (0.6) 1.6 (0.9) 2.0 (1.0) 1.8 (0.9)
Proteinuria (g/24 h) 3.3 (6.2) 1.7 (1.2) 2.3 (2.2) 2.3 (1.9) 2.6 (2.1) 3.3 (4.6)
Urea (mg/dL) 50.3 (18.3) 48.9 (20.9) 52.9 (18.8) 62.5 (28.4) 61.8 (27.6) 58.0 (26.9)
Hemoglobin (g/dL) 13.3 (1.9) 13.4 (1.6) 13.2 (1.6) 12.8 (1.7) 12.7 (2.0) 12.7 (1.8)
Laboratory measurements found in the study group from baseline to end of the study. Data shown are mean ± SD of all subjects (N = 18). For 
the intention to treat analysis (ITT), all patients as originally assigned to the study, including those who did not comply with the intervention 
protocol and those who had not completed the intervention, were included.
(2/18), and headache 11.1% (2/18). Fatigue was mild and did 
not interfere with activities of daily living. Most of the side 
effects reported were transient or required only symptom-
atic management, and none of the events required treatment 
after the first 3 months. None of the adverse events described 
Table 3. Patient characteristics at the end of protocol.
Patient Age 
(years)
CKD 
stage 
Creatinine 
depuration 
mL/min
eGFR  
(mL/min/ 
1.73 m2)
1 20 4 28.84 23
2 36 3a 54.67 47
3 23 5 16.28 11
5 19 3a 57.63 46
7 15 1 137.3 120
8 21 4 30.3 22
9 15 1 155.79 152
10 29 3b 49.15 38
11 43 4 35.63 24
12 14 4 21.46 21
13 17 3b 39.88 37
15 39 2 112.04 85
17 26 2 60.54 60
18 23 4 30.58 18
CKD: chronic kidney disease; eGFR: estimated glomeru-
lar filtration rate; Creatinine depuration was calculated by 
COCKROFT-GAULT formula.
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Figure 2. ITT and PP analysis for proteinuria levels.
IIT, Intention to treat analysis; PP, per-protocol.
Table 4. PP analysis of average laboratory measurements throughout the study.
Basal (SD) Month 12  
(SD)
Month 24 
(SD)
Month 36  
(SD)
Month 48  
(SD)
Month 60 
(SD)
GFR (mL/min/1.73 m2) 54.2 (28.0) 62.1 (41.5) 60.2 (38.6) 58.5 (48.5) 54.1 (45.7) 58.9 (49.3)
Creatinine (mg/dL) 1.9 (0.9) 1.8 (0.9) 1.9 (0.9) 2.2 (1.1) 2.5 (1.2) 3.2 (1.6)
Cystatin C (mg/L) 1.5 (0.5) 1.5 (0.7) 1.6 (0.7) 1.5 (0.9) 1.9 (0.9) 2.0 (0.9)
Proteinuria (g/24 h) 4.0 (8.3) 1.5 (1.2) 2.3 (2.4) 2.5 (2.0) 2.7 (1.8) 3.3 (4.6)
Urea (mg/dL) 47.6 (20.0) 43.2 (17.2) 53.4 (19.6) 60.1 (22.4) 60.0 (22.2) 65.3 (28.5)
Hemoglobin (g/dL) 13.5 (1.5) 13.3 (1.3) 13.2 (1.4) 12.7 (1.2) 13.0 (2.0) 12.5 (1.9)
Laboratory measurements found in the study group from baseline to end of the study. Data shown are mean ± SD. For the 
per-protocol (PP) analysis, only subjects who complied with intervention protocols and completed the intervention were 
included (n = 14). GFR: glomerular filtration rate; SD: standard deviation.
to maintain their GFR with a slight improvement, although 
with minimal variation after 12 months (+8.4 and  + 
7.9 mL/min/1.73m2 for ITT and PP analysis, respectively). 
Minimal changes were reported after 36 months, with an 
increase of +5.5 and +4.3 mL/min/1.73m2 (ITT and PP anal-
ysis, respectively), compared with baseline; while at the end 
of 60 months’ follow-up, no decline in GFR was reported 
(+4.2 and +4.7 mL/min/1.73m2 from baseline in ITT and PP, 
respectively). Thus, the nondeclining evidence suggests good 
outcomes in our study group (Tables 2 and 4). It is import-
ant to keep in mind data shown by Cho et al. where patients 
without PFD treatment had a diminished GFR at a monthly 
median of −0.61 mL/min/1.73 m2; however, once the same 
study group received rapid-released or regular PFD, monthly 
GFR declined at −0.45 mL/min/1.73 m2 (26). Sharma et al. 
administrated pirfenidone in patients with diabetic nephrop-
athy. Patients presented a baseline estimated GFR (eGFR) 
of 20 to 75 mL/min per 1.73 m2. They were provided two 
doses of pirfenidone 1200 mg/day and 2400 mg/day. The 
mean eGFR increased in the 1200 mg/day group (+3.3 ± 8.5 
mL/min/1.73 m2), whereas the 2400 mg/day group presented 
a change in eGFR of −1.9 ± 6.7 mL/min/1.73 m2 after 12 
months of treatment (14). Noteworthy, regular standard- 
release PFD capsules were administrated in this study as 
opposed to our study where PR-PFD tablets were used. 
Our results are similar in the maintenance of renal function 
and additionally, most of the side effects reported with the 
PR-PFD tablets used in this study were milder, transient, or 
required only symptomatic management; none of the events 
required treatment after the first 3 months.
Noteworthy, recent studies with PFD in kidney disease 
have described no effect of PFD in proteinuria (14, 26), 
although in our study we showed that 24 h proteinuria rate 
slightly improved during PFD treatment, which avoids an 
increase in proteinuria that is seen at the end of  follow-up. 
required PR-PFD suspension or developed photosensitivity 
contrary to previously reported data (14, 26, 28–30).
It is also clear that the new formulation of prolonged- 
release pirfenidone tablets used in this study causes only 
minor secondary effects, which dissapeared after the first 
3 months of treatment. Furthermore, when compared 
with previous studies, prolonged-release PFD induced less 
intense and less frequent secondary events than regular 
rapid- released PFD-capsules used in the studies of Cho and 
Sharma (14, 26). Taken all together, these studies suggest 
that PR-PFD used here is safe and well tolerated.
Discussion
In this study, both the ITT analysis and PP analysis showed 
that all patients enrolled in this pilot clinical trial were able 
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that PFD bioavailability levels (1.2 µg/mL) were raised after 
1 h of intake, while a maximum plasma level of 2.4 µg/mL 
was found after 4 h of ingestion (Figure  3). According to 
these results, we can also conclude that this pharmaceuti-
cal presentation of 600 mg prolonged-release tablets has an 
improved and suitable bioavailability with a mean t1/2 of 10.79 
h. Thus, it does represent an adequate pharmacological pre-
sentation to maintain PFD plasma levels within therapeutic 
ranges improving outcomes, patient’s adherence to treatment, 
and reducing incidence of side effects.
The standard-released PFD actually marketed as 257 mg 
capsules has been shown to cause intense gastrointestinal side 
effects in several clinical trials, resulting in a high dropout rate 
of patients (up to 42%) in different clinical trials, probably 
due to its high peak of fast absorption. Prolonged-released 
tablets (600 mg) were specifically designed to circumvent the 
high peak, maintaining total daily pharmaceutically stable 
levels. Figure 3 shows a dissimilar pharmacokinetics for the 
standard and prolonged-release formulations.
Therefore, data presented here suggest that CKD man-
agement with PR-PFD might be a suitable adjuvant therapy 
due to its mechanism of action, which inhibits activation 
of pro-inflammatory and pro-fibrogenic cytokines, and 
increases synthesis and activity of matrix metalloproteinases 
(MMPs) controlling the loss of renal parenchyma, character-
istic in kidney damage and renal fibrosis.
Recently, Ikezoe et al. evaluated the relationship of CKD 
to clinical features and outcomes in patients with IPF. Some 
of the patients were treated with pirfenidone. In this case, the 
use of pirfenidone to treat IPF was not associated with sur-
vival. They concluded that a substantial percentage of IPF 
patients have CKD; that CKD with a low eGFR was associ-
ated with decreased survival in IPF; and that the impact on 
Comparison between basal levels and after 12, 36, and 
60  months shown in Tables 2 and 4 showed no decline, 
supporting the benefit of adding PR-PFD to improve pro-
teinuria rate; this is a relevant finding due to the fact that 
proteinuria is an important indicator of adverse outcomes in 
CKD and its strong association with GFR and adverse clin-
ical outcomes (31, 32). Measurement of creatinine, cystatin 
C, urea, and hemoglobin as visible in Tables 2 and 4 showed 
no considerable modifications across the study.
Also, in this study, we achieved a high adherence rate 
to treatment in comparison with other studies with PFD. 
Here, two patients decided to stop therapy after 27 months 
of  treatment, one patient stopped therapy after 45 months 
since he became a transplant recipient, and one patient was 
excluded from the study after 54 months of  treatment due 
to loss of  adherence. High adherence to the medication 
results could be attributed to the use of  a new pharmaco-
logical form of  the compound (prolonged-released tablets), 
which diminished the rate and severity of  side effects as 
published by Cho et al. (26), Gahl et al. (28), Bowen et al. 
(29), and Nagai et al. (30) where regular standard- release 
PFD capsules were used. Moreover, initiation of  drug 
administration in an escalated manner was necessary to 
improve tolerance.
Shi et al. previously published PFD pharmacokinetics in 
healthy volunteers, describing a rapid absorption within 1–2 
h after oral administration and cleared from plasma with a 
half-life of 2.1 ± 0.4 h, with a maximum plasma concentra-
tion occurring 0.33–1 h after administration. Mean t1/2 ranged 
from 2 to 2.5 h in subjects with an oral CL/F of approximately 
9.6 L/h (33). We have focused our research on PFD 600 mg 
prolonged-release tablets according to the pharmacokinetic 
studies carried out by our team (unpublished data) showing 
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renal function and disease outcomes of pirfenidone should 
be elucidated in prospective clinical trials (34).
In summary, pharmacokinetic studies and pilot studies 
show that pirfenidone is safe in the CKD setting. One goal 
of this pilot protocol was to provide a basis for the safe use 
of a prolonged-release pirfenidone pharmaceutical-form to 
minimize the said effects of the standard formulation of pir-
fenidone in patients with CKD and enhance the treatment 
adherences. Kidney scarring is a dominant factor in the 
development of kidney disease (15). Hypothetically, pirfeni-
done administration at early times after patients are diag-
nosed with CKD will prevent the progression of renal tissue 
fibrosis and consequently improve renal function.
We are aware of the limitations of our work regarding 
the limited number of patients and the lack of a placebo- 
controlled group. However, the main strength of this study is 
the long term of 60 months of patient follow-up. As far as we 
know, there are no other protocols present in a clinical scheme 
similar to the one used here, which by itself  is noteworthy.
In Mexico, as well as in many developing countries, there 
are no public health policies regarding the prophylactic and 
therapeutic approach for CKDs and, therefore, the eco-
nomic burden of treating the devastating complications of 
this group of diseases have always taken their toll. Thus, new 
pharmacological approaches are required to decrease this 
pathologic condition.
Conclusion
In conclusion, long-term, prolonged-released PFD could be 
safely used as an adjuvant therapy in patients with CKD. 
We understand the limitations of our study in terms of 
controlling the protocol. Although promising, these results 
need to be endorsed under the perspective of a double-blind, 
 placebo-controlled, clinical scenario.
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